Epigenetic therapy attenuates oxidative stress in BMSCs during ageing. Issue 2 (7th December 2021)

• Record Type: Journal Article
• Authors: Su, Xiaoxia; Zhang, Haoyu; Lei, Fengzhen; Wang, Rui; Lin, Tingting; Liao, Li
• Is Part Of: Journal of cellular and molecular medicine. Volume 26:Issue 2(2022)
• Page Start: 375
• Page End: 384
• Publication Date: 2021-12-07
• Subjects: bone remodelling -- cell differentiation -- epigenetics -- oxidative stress -- stem cells; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.17089
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Oxidative stress, a hallmark of ageing, inhibits the osteogenic differentiation of bone marrow‐derived mesenchymal stem cells in long bone. The dysfunction of the cellular antioxidant defence system is a critical cause of oxidative stress, but the mechanism of the decline of antioxidant defence in senescent stem cells remains elusive. Here, we found that EZH2, an epigenetic regulator of histone methylation, acted as a suppressor of the antioxidative defence system in BMSCs from the femur. The increased EZH2 led to a decrease in the levels of antioxidant enzymes and exaggerated oxidative damage in aged BMSCs, resulting in the defect of bone formation and regeneration. Mechanistically, EZH2 enhanced the modification of H3K27me3 on the promoter of Foxo1 and suppressed its function to activate the downstream genes in antioxidant defence. Moreover, epigenetic therapy targeting EZH2‐mediated H3K27me3 modification largely recovered the antioxidant defence in BMSCs and attenuate oxidative damage, leading to the recovery of the osteogenesis in old BMSCs. Taken together, our findings revealed novel crosstalk between histone epigenetic modification and oxidative stress during stem cell ageing, suggesting a possibility of epigenetic therapy in the recovery of BMSCs senescence and treatment of age‐related bone disease.